Daclatasvir is an orally available inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, with potential activity against HCV. Daclatasvir use with Sofosbuvir with or without Ribavirin to treat HCV genotype 1 and 3 infections. Daclatasvir was FDA-approved in July 2015.
SynZeal offers all Daclatasvir related impurities standards with certified COA and characterization data like IR, Mass, HPLC, purity, NMR & TGA report. We also provide CMR, DEPT and detailed structure characterization report as per requirements. Daclatasvir related standards are being used by major pharmaceutical companies across the globe for their ANDA/DMF filing.